Trade Summary

2 days ago, Torley Helen, serving as PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 1,923 shares at $79.77 per share, for a total transaction value of $153,390.63. Following this transaction, Torley Helen now holds 767,780 shares of HALO.

This sale represents a 0.25% decrease in Torley Helen's stake in the company.

The trade was executed on Wednesday, July 8, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, July 9, 2026 at 5:19 PM ET, 1 day after the trade was made.

HALOZYME THERAPEUTICS, INC. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.